Bayer secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.

Acadia Pharmaceuticals is adding a novel pain portfolio to the company’s pipeline through the acquisition of Texas-based CerSci Therapeutics for $52.5 million.

Zymeworks and longtime partner Merck signed a new license agreement. Merck was granted the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.

In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share.

Jaydev Thakkar was named chief operating officer and Milan Shah was appointed chief technology officer of Biofourmis

Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.

Array BioPharma sued AstraZeneca, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

Biogen Inc. said it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company’s patents covering multiple sclerosis drugs.

Merck & Co. was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit over Gilead Sciences’ blockbuster hepatitis C drugs Sovaldi and Harvoni.

France’s Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being.